Behold.ai vs Gleamer (2026)
Two European radiograph companies separated by the most consequential decision in imaging AI, whether a human still looks. Behold auto reports chest films it classifies as high confidence normal, removing them from the worklist entirely, and it publishes the performance numbers that autonomy requires in peer reviewed venues. Gleamer detects fractures, effusions and dislocations on trauma radiographs with the reader deciding every case, and holds a clearance covering adult and paediatric use reported to be unique in that segment. They read different films, so a department would rarely choose between them. What the pair shows is the evidence gradient: the moment a product stops handing a study to a radiologist, the false negative rate at its operating threshold stops being interesting and becomes the only thing that matters.
- It removes studies from the worklist entirely by auto reporting chest radiographs classified as high confidence normal, which is genuine autonomy inside a bounded task.
- The numbers that matter for that autonomy are published in peer reviewed venues, and the confidence threshold is itself the governance mechanism.
- For a service drowning in normal chest films, removing them from the queue is a different economic proposition from reading them faster.
- Its trauma radiography clearance covers adult and paediatric use, reported to be unique in that segment, with a strong clearance study design behind it.
- The reader retains the decision on every study, which is the conventional and lower risk configuration.
- Distribution through several imaging platforms means adoption does not depend on a single integration path.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Behold.ai and Gleamer are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Behold.ai | Gleamer |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2015 | 2017 |
| Headquarters | London, United Kingdom | Paris, France |
| Website | behold.ai | gleamer.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Behold.ai its top capability grade on AI Centrality and Autonomy and Oversight Model. Set against Gleamer, Behold.ai grades higher on Autonomy and Oversight Model. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Gleamer its top capability grade on AI Centrality, Clinical and Operational Evidence and FDA and Regulatory Status. Set against Behold.ai, Gleamer grades higher on several axes, including Model Supply Chain Disclosure, Clinical and Operational Evidence and FDA and Regulatory Status. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Behold.ai or Gleamer?
On the axes where the AI Health Index separates them, Behold.ai grades higher on Autonomy and Oversight Model, and Gleamer grades higher on several axes, including Model Supply Chain Disclosure, Clinical and Operational Evidence and FDA and Regulatory Status. Gleamer leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Behold.ai and Gleamer differ most?
The widest separation the AI Health Index records between Behold.ai and Gleamer is on FDA and Regulatory Status, where Behold.ai grades C and Gleamer grades A. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Behold.ai and Gleamer grade the same?
The AI Health Index grades Behold.ai and Gleamer the same on several axes, including AI Centrality, Model and Technology Transparency and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Behold.ai and Gleamer not disclosed?
At the last review, at least one of Behold.ai and Gleamer published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The autonomy difference sets the evidence bar: an auto reporting classifier needs its false negative rate at the operating threshold published and locally revalidated, because a missed finding on an auto reported film is never seen by anyone, while a detection aid leaves the radiologist reading every study.
Behold's regulatory standing is multi jurisdictional and unsettled and its corporate history complicates the identity of the contracting entity, both of which should be established before deployment. Neither publishes a security attestation or pricing.